Literature DB >> 10733546

Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: an outcome-oriented decision analysis.

P E Majno1, F P Sarasin, G Mentha, A Hadengue.   

Abstract

Two treatments are accepted for patients with solitary hepatocellular carcinoma </=5 cm in size and with preserved hepatic function: (1) liver resection, which can be performed without delay but has a high recurrence rate, and (2) liver transplantation, which has a better long-term survival, but is not easily available because grafts are scarce. A third possibility is to offer liver resection first and liver transplantation for tumor recurrence or deteriorating liver function ("salvage" transplantation). We investigated the implications of such a strategy with a Markov-based decision analytic model. In a scenario assuming intermediate values for 4 main variables (12-month waiting list; tumor progression outside transplantation criteria: 4% per month; recurrence after resection: 20% per year; recurrences eligible for transplantation: 60%), the life expectancy was 8.8 years for primary transplantation versus 7.8 years for primary resection and salvage transplantation, with a calculated use of grafts at 5 years of 52% for primary transplantation versus 23% for salvage transplantation. This study estimates of the survival and graft-saving of a strategy of primary resection and salvage transplantation according to variables that are to some extent predictable. This strategy may be a rational way to cope with lengthening waiting lists, especially for patients with tumors close to the limit for transplantation criteria, if the results of liver resection are good, if patients with the lowest risks of recurrence can be selected, and if a strict follow-up can detect recurrences when the patients are still transplantable.

Entities:  

Mesh:

Year:  2000        PMID: 10733546     DOI: 10.1053/he.2000.5763

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  80 in total

1.  The relative net health benefit of liver resection, ablation, and transplantation for early hepatocellular carcinoma.

Authors:  Gaya Spolverato; Alessandro Vitale; Aslam Ejaz; Yuhree Kim; Shishir K Maithel; David P Cosgrove; Timothy M Pawlik
Journal:  World J Surg       Date:  2015-06       Impact factor: 3.352

2.  Non-surgical treatment of hepatocellular carcinoma.

Authors:  Philip J Johnson
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

Review 3.  Management of solitary 1 cm to 2 cm liver nodules in patients with compensated cirrhosis: a decision analysis.

Authors:  Karen E Bremner; Ahmed M Bayoumi; Morris Sherman; Murray D Krahn
Journal:  Can J Gastroenterol       Date:  2007-08       Impact factor: 3.522

4.  Liver transplantation, liver resection, and transarterial chemoembolization for hepatocellular carcinoma in cirrhosis: which is the best oncological approach?

Authors:  Georgios C Sotiropoulos; Nina Drühe; George Sgourakis; Ernesto P Molmenti; Susanne Beckebaum; Hideo A Baba; Gerald Antoch; Philip Hilgard; Arnold Radtke; Fuat H Saner; Silvio Nadalin; Andreas Paul; Massimo Malagó; Christoph E Broelsch; Hauke Lang
Journal:  Dig Dis Sci       Date:  2008-12-05       Impact factor: 3.199

Review 5.  Liver resection and transplantation in hepatocellular carcinoma.

Authors:  J Belghiti; D Fuks
Journal:  Liver Cancer       Date:  2012-09       Impact factor: 11.740

Review 6.  Hepatocellular carcinoma: is current therapy really altering outcome?

Authors:  P J Johnson
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

Review 7.  Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation.

Authors:  Maurizio Pompili; Giampiero Francica; Francesca Romana Ponziani; Roberto Iezzi; Alfonso Wolfango Avolio
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

8.  Primary surgical resection versus liver transplantation for transplant-eligible hepatocellular carcinoma patients.

Authors:  Robert J Wong; James Wantuck; Antonia Valenzuela; Aijaz Ahmed; Clark Bonham; Amy Gallo; Marc L Melcher; Glen Lutchman; Waldo Concepcion; Carlos Esquivel; Gabriel Garcia; Tami Daugherty; Mindie H Nguyen
Journal:  Dig Dis Sci       Date:  2013-11-27       Impact factor: 3.199

9.  Comparison of Salvage Living Donor Liver Transplantation and Local Regional Therapy for Recurrent Hepatocellular Carcinoma.

Authors:  Chee-Chien Yong; Ming-Chao Tsai; Chih-Che Lin; Chih-Chi Wang; Sheng-Nan Lu; Chao-Hung Hung; Tsung-Hui Hu; Chao-Long Chen
Journal:  World J Surg       Date:  2016-10       Impact factor: 3.352

10.  Good longterm survival after primary living donor liver transplantation for solitary hepatocellular carcinomas up to 8 cm in diameter.

Authors:  Wing Chiu Dai; See Ching Chan; Kenneth S H Chok; Tan To Cheung; William W Sharr; Albert C Y Chan; Simon H Y Tsang; James Y Y Fung; Ronnie T P Poon; Sheung Tat Fan; Chung Mau Lo
Journal:  HPB (Oxford)       Date:  2014-01-28       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.